MERIT-HF: Impact of ß-blocker dose on outcomes in patients with heart failure
In a post hoc subgroup analysis, the MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure) researchers examined the relation of ß-blocker dose to clinical outcomes.1
Randomized placebo-controlled trials of ß-blocker therapy in heart failure show that patients treated with ß-blockade benefit with reductions in morbidity and mortality.2-5
However, because not all patients in these studies reached the targeted ß-blocker dose, clinicians have questioned whether maximum doses are necessary to benefit from treatment. The current analysis has produced additional information on this issue.
References are listed at the end of the Data Alert.
Download DA13.ppt (6 slides - 0.9MB)